Cullinan Associates Inc. Buys 11,401 Shares of Axon Enterprise, Inc $AXON

Cullinan Associates Inc. raised its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 2,280.2% during the 3rd quarter, Holdings Channel reports. The fund owned 11,901 shares of the biotechnology company’s stock after acquiring an additional 11,401 shares during the period. Cullinan Associates Inc.’s holdings in Axon Enterprise were worth $5,028,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of AXON. Ethic Inc. lifted its holdings in Axon Enterprise by 9,571.5% during the 3rd quarter. Ethic Inc. now owns 618,108 shares of the biotechnology company’s stock worth $261,163,000 after purchasing an additional 611,717 shares during the last quarter. 180 Wealth Advisors LLC boosted its stake in Axon Enterprise by 202.8% in the 3rd quarter. 180 Wealth Advisors LLC now owns 38,324 shares of the biotechnology company’s stock valued at $16,193,000 after purchasing an additional 25,669 shares during the period. StoneX Group Inc. boosted its stake in Axon Enterprise by 3,123.1% in the 3rd quarter. StoneX Group Inc. now owns 28,428 shares of the biotechnology company’s stock valued at $12,011,000 after purchasing an additional 27,546 shares during the period. Verus Capital Partners LLC grew its holdings in Axon Enterprise by 30.6% in the 3rd quarter. Verus Capital Partners LLC now owns 584 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 137 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in Axon Enterprise by 17.7% in the 3rd quarter. Parallel Advisors LLC now owns 1,383 shares of the biotechnology company’s stock valued at $584,000 after buying an additional 208 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick Smith sold 10,000 shares of Axon Enterprise stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total value of $5,089,900.00. Following the completion of the transaction, the chief executive officer directly owned 3,118,012 shares of the company’s stock, valued at $1,587,036,927.88. The trade was a 0.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey Kunins sold 9,605 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the sale, the insider owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. The trade was a 8.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,397 shares of company stock valued at $21,234,034 over the last 90 days. 4.20% of the stock is currently owned by insiders.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Stock Down 18.2%

NASDAQ AXON opened at $313.00 on Friday. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a 1-year low of $307.00 and a 1-year high of $665.07. The company has a 50 day moving average of $441.53 and a 200-day moving average of $475.20. The company has a market cap of $25.43 billion, a price-to-earnings ratio of 100.32, a PEG ratio of 5.95 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The company had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a return on equity of 3.95% and a net margin of 7.56%. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.17 EPS. On average, equities research analysts expect that Axon Enterprise, Inc will post 2.10 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AXON shares. Raymond James Financial set a $675.00 price objective on Axon Enterprise in a research report on Thursday, October 15th. Craig Hallum cut shares of Axon Enterprise from a “buy” rating to a “hold” rating and set a $390.00 target price for the company. in a research report on Friday. Argus upped their price target on shares of Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Tuesday. Finally, Royal Bank Of Canada lowered their price target on shares of Axon Enterprise from $735.00 to $615.00 and set an “outperform” rating on the stock in a research report on Friday. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $631.35.

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.